Geranylgeranyl diphosphate synthase

An emerging therapeutic target

A. J. Wiemer, D. F. Wiemer, Raymond Hohl

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Proteins modified post-translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years, the study of protein geranylgeranylation has advanced tremendously in both cellular and animal models. The advances in our understanding of the biological roles of geranylgeranylated proteins have been paralleled by advances in the medicinal chemistry of geranylgeranylation inhibitors such as those that target geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS). Although these findings provide the rationale for further development of geranylgeranylation as a therapeutic target, more advanced studies on the efficacy of this approach in various disease models will be required to support translation to clinical studies. This article attempts to describe the advances in (and the challenges of) validation of GGDPS as a novel therapeutic target and assesses the advantages of targeting GGDPS relative to other enzymes involved in geranylgeranylation.

Original languageEnglish (US)
Pages (from-to)804-812
Number of pages9
JournalClinical pharmacology and therapeutics
Volume90
Issue number6
DOIs
StatePublished - Dec 1 2011

Fingerprint

Farnesyltranstransferase
Prenylation
Protein Prenylation
Pharmaceutical Chemistry
Therapeutics
Proteins
Animal Models
Enzymes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{1a12783a328f480690c7ccbb97e1480f,
title = "Geranylgeranyl diphosphate synthase: An emerging therapeutic target",
abstract = "Proteins modified post-translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years, the study of protein geranylgeranylation has advanced tremendously in both cellular and animal models. The advances in our understanding of the biological roles of geranylgeranylated proteins have been paralleled by advances in the medicinal chemistry of geranylgeranylation inhibitors such as those that target geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS). Although these findings provide the rationale for further development of geranylgeranylation as a therapeutic target, more advanced studies on the efficacy of this approach in various disease models will be required to support translation to clinical studies. This article attempts to describe the advances in (and the challenges of) validation of GGDPS as a novel therapeutic target and assesses the advantages of targeting GGDPS relative to other enzymes involved in geranylgeranylation.",
author = "Wiemer, {A. J.} and Wiemer, {D. F.} and Raymond Hohl",
year = "2011",
month = "12",
day = "1",
doi = "10.1038/clpt.2011.215",
language = "English (US)",
volume = "90",
pages = "804--812",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

Geranylgeranyl diphosphate synthase : An emerging therapeutic target. / Wiemer, A. J.; Wiemer, D. F.; Hohl, Raymond.

In: Clinical pharmacology and therapeutics, Vol. 90, No. 6, 01.12.2011, p. 804-812.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Geranylgeranyl diphosphate synthase

T2 - An emerging therapeutic target

AU - Wiemer, A. J.

AU - Wiemer, D. F.

AU - Hohl, Raymond

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Proteins modified post-translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years, the study of protein geranylgeranylation has advanced tremendously in both cellular and animal models. The advances in our understanding of the biological roles of geranylgeranylated proteins have been paralleled by advances in the medicinal chemistry of geranylgeranylation inhibitors such as those that target geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS). Although these findings provide the rationale for further development of geranylgeranylation as a therapeutic target, more advanced studies on the efficacy of this approach in various disease models will be required to support translation to clinical studies. This article attempts to describe the advances in (and the challenges of) validation of GGDPS as a novel therapeutic target and assesses the advantages of targeting GGDPS relative to other enzymes involved in geranylgeranylation.

AB - Proteins modified post-translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years, the study of protein geranylgeranylation has advanced tremendously in both cellular and animal models. The advances in our understanding of the biological roles of geranylgeranylated proteins have been paralleled by advances in the medicinal chemistry of geranylgeranylation inhibitors such as those that target geranylgeranyl transferases I and II and geranylgeranyl diphosphate synthase (GGDPS). Although these findings provide the rationale for further development of geranylgeranylation as a therapeutic target, more advanced studies on the efficacy of this approach in various disease models will be required to support translation to clinical studies. This article attempts to describe the advances in (and the challenges of) validation of GGDPS as a novel therapeutic target and assesses the advantages of targeting GGDPS relative to other enzymes involved in geranylgeranylation.

UR - http://www.scopus.com/inward/record.url?scp=81355135331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355135331&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.215

DO - 10.1038/clpt.2011.215

M3 - Article

VL - 90

SP - 804

EP - 812

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -